Cardiol Therapeutics is developing cannabidiol-based therapies targeting inflammation and fibrosis in heart diseases such as pericarditis, myocarditis, and heart failure. Their clinical-stage treatments aim to improve patient outcomes by addressing the underlying mechanisms that contribute to these debilitating cardiac conditions.
Funding
$50.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart diseases like pericarditis, myocarditis, and heart failure are often characterized by inflammation and fibrosis, leading to impaired cardiac function and significant morbidity. Current treatment options may not fully address the underlying inflammatory and fibrotic mechanisms contributing to these conditions. This can result in limited efficacy and persistent symptoms for affected patients.
Solution
Cardiol Therapeutics is a clinical-stage life sciences company focused on developing therapies that target inflammation and fibrosis in heart disease. Their investigational therapies, including CardiolRx, are designed to modulate the immune response and reduce fibrosis within the heart. By targeting these underlying mechanisms, Cardiol Therapeutics aims to improve cardiac function, reduce symptoms, and enhance the overall quality of life for patients suffering from pericarditis, myocarditis, and heart failure. The company is currently conducting clinical trials to evaluate the safety and efficacy of its therapies in rare cardiac conditions.
Target Audience
The primary target audience includes patients suffering from heart diseases characterized by inflammation and fibrosis, such as pericarditis, myocarditis, and heart failure, as well as the physicians who treat these conditions.
Features
- Focus on anti-inflammatory and anti-fibrotic mechanisms in heart disease
- CardiolRx: a pharmaceutically produced cannabidiol formulation
- Clinical trials for recurrent pericarditis, myocarditis, and heart failure with preserved ejection fraction (HFpEF)
- Collaboration with international research and clinical centers